Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of Clinical Sites for the Undiagnosed Diseases Network (U01 - Clinical Trial Not Allowed)
ID: 342659Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) intends to publish a Funding Opportunity Announcement (FOA) for a Limited Competition aimed at the continuation of Clinical Sites for the Undiagnosed Diseases Network (UDN). This opportunity is specifically for institutions and Program Directors/Principal Investigators who have previously received NIH funding under the UDN program and allows them to compete for an additional year of funding to sustain their participation, enhance collaborations, and develop sustainability plans as the network transitions to a national resource. The estimated total program funding is $6.5 million, with an award ceiling of $400,000 and an expected 11 awards to be made. Interested applicants should prepare for the anticipated application due date in September 2022 and may contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373 for further information.

    Point(s) of Contact
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the establishment of Diagnostic Centers of Excellence (DCoE) as part of the Undiagnosed Diseases Network (UDN). The initiative aims to enhance the diagnostic journey for patients with undiagnosed diseases by creating a self-sustained network that provides expert diagnostic services and fosters scientific discovery, with a focus on utilizing genomics data. Eligible applicants will be clinical sites in the U.S. that can demonstrate the necessary infrastructure and expertise to conduct clinical evaluations and DNA sequencing, with the opportunity to enroll a minimum of five participants annually. Interested parties can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373 for further details. The program announcement is expected to be published in spring 2023, with applications due in early summer 2023, and the maximum period of performance for awarded projects will be five years.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)" aimed at enhancing resources for investigating undiagnosed diseases through a network of clinical sites. This initiative seeks to designate successful applicants as Diagnostic Centers of Excellence (DCoE), which will be responsible for generating clinical data to be shared with the Data Management Coordinating Center (DMCC), thereby promoting collaboration among clinicians and researchers to improve diagnostic capabilities, particularly for health disparity populations. The program does not provide direct budgetary support but allows successful applicants to apply for subawards for research activities, with applications open from April 15, 2023, until the final deadline of May 15, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a limited competition for the renewal of existing clinical trial cooperative agreement awards (U01) that require additional time and resources to complete ongoing research on neurological disorders. This funding opportunity is specifically aimed at supporting extramural research efforts and emphasizes the importance of collaboration between NIH and award recipients to achieve significant advancements in the field. Eligible applicants include various federal entities, independent school districts, and tribal organizations, with the application submission period opening on February 5, 2025, and deadlines extending throughout the year. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-149.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required). This initiative aims to provide statistical expertise for the design, conduct, and data management of multi-center clinical trials, particularly focusing on late-phase treatment trials across various cancer types and patient demographics. The funding, estimated at $47 million, will support approximately five awards, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, interested applicants should prepare their proposals in advance of the anticipated timeline.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.